Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
KALA | NASDAQ | USD | Real-time | |
0JQ2 | London | USD | Real-time | |
27F0 | Frankfurt | EUR | Delayed |
KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company’s product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.
Name | Age | Since | Title |
---|---|---|---|
Justin Hanes | - | - | Founder & Chair of the Scientific Advisory Board |
Andrew I. Koven | 64 | 2017 | Lead Independent Director |
Mark T. Iwicki | 56 | 2015 | Chairman & CEO |
Howard B. Rosen | 65 | 2014 | Independent Director & Member of Advisory Board |
Marjan Farid | 49 | 2022 | Independent Director |
Colin R. Gardner | - | - | Member of Scientific Advisory Board |
Bennett M. Shapiro | 84 | - | Member of Scientific Advisory Board |
Ronald Lee Krall | - | - | Member of Scientific Advisory Board |
Peter Barton Hutt | 89 | - | Member of Scientific Advisory Board |
Gregory D. Perry | 64 | 2018 | Independent Director |
Jonathan Todd Silverstein | 57 | 2016 | Board Observer |
Mark S. Blumenkranz | 73 | 2021 | Independent Director |
Charles Daniel Myers | 70 | 2021 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review